24. Bento L, Diaz-Lopez A, Barranco G, et al. Newprognosis score including absolute lymphocytes/monocytes ratio and beta2 microglobulin in patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP: Spanis...
The Revised International Prognostic Index (R-IPI) Score Is Predictive Of Survival In Aggressive Transformed Lymphomas (TL) From Low Grade Non-Hodgkin Lymphomas In The Chemoimmunotherapy EraTsao Christina, MD
(1.9, NR)PFS rate at 12mo, %43.538.1OS rate at 12mo, %78.084.7*Measured by tumor proportion scoreDefined as the proportion of treated pts with a best overall response of confirmed complete response, partial response or stable disease Conclusions These results suggest clinical benefit from two...
(range 19–80 years), which was similar to three other recent studies of Chinese DLBCL patients14,15,16, but much younger than those reported for DLBCL populations in the Western countries17,18. Based on the IPI score, 58 patients (27.0%) were in the intermediate-high or high-risk ...
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer 2014;111:55-60.Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, et al. C-reactive protein...
C-reactive protein level is a prognostic indicator for sur- vival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014, 111(1): 55-60.C-reactive protein level is a prognostic indicator for survival and improves the predictive ...
This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. Patients and methods Eligible pts were aged 18-65 years with stage II-IV untreated DLBCL and an International Prognostic Index (IPI) score of 3...
By sAAIPI score, 4‐year RFS was 80% for a score of 0, 90% for a score of 1, and 0% for scores of 2 and 3. Patients with low‐ and low‐intermediate risk sAAIPI scores of 0 and 1 had improved RFS as compared to patients with sAAIPI scores of 2 and 3 (87% v 0%, p...
(1.9, NR)PFS rate at 12mo, %43.538.1OS rate at 12mo, %78.084.7*Measured by tumor proportion scoreDefined as the proportion of treated pts with a best overall response of confirmed complete response, partial response or stable disease Conclusions These results suggest clinical benefit from two...